Company intelligence / Profile preview

Vaporox

Denver, Colorado, United Statesvaporox.com ↗

Ownership: Private
Development stage: Commercial

Overview

The VHT system has demonstrated healing rates of approximately 70–85% for chronic wounds and diabetic foot ulcers that were unresponsive to standard treatments. Clinical studies show the addition of VHT to standard wound care doubles or triples healing rates and delivers results in under 20 weeks. The FDA-cleared VHT device promotes revascularization and tissue growth using ultrasonic mist and concentrated oxygen.

Therapeutic areas: Dermatology
Modalities: DeviceNon-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Bioventus (minority investor with phased acquisition option)

Beyond the preview

Go deeper on Vaporox.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Vaporox.

Explore the full profile